Transchem Ltd.
BSE: TRANSCHEM · Pharmaceuticals · sector
₹412.45BSE close 2026-10-26
Key numbers
Market cap₹505 cr
Price₹412.45
52w high / low₹433 / ₹62
P/E75.1xSector median 27.9x
P/B6.0xSector median 2.9x
Book value₹68.3
Dividend yield–Sector median 0.48%
ROE8.2%Sector median 11.7%
ROCE10.3%Sector median 12.3%
OPM–Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover1,025.9x
Current ratio21.39x
Sales growth 3y–Sector median +9.6%
Profit growth 3y+51.3%Sector median +13.3%
PEG1.46x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹42 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 1,025.9x in the last 12 months.
- Other income was 190% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹412.45 on 2026-10-26: -4.7% from the 52-week high, +561.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹415.15 · low ₹33.98
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 2 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -0 | -0 | -1 | -1 | -1 | -1 |
| OPM % | -19.8% | – | – | – | – | – |
| Other income | 2 | 2 | 2 | 2 | 4 | 5 |
| Net profit | 1 | 1 | 1 | 1 | 2 | 3 |
| EPS (₹) | 0.60 | 0.81 | 0.56 | 0.43 | 1.71 | 2.79 |
| Revenue YoY | -100.0% | – | ||||
| Profit YoY | +186.3% | +245.5% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | – | – | 0 | 3 | 0 | 0 |
| EBITDA | -3 | -2 | -2 | -1 | -4 | -4 |
| Net profit | 3 | 1 | 4 | 5 | 4 | 7 |
| EPS (₹) | 2.34 | 1.01 | 3.43 | 4.27 | 3.51 | 5.49 |
| Revenue growth | – | – | +541.5% | -100.0% | – | |
| Profit growth | -56.8% | +238.7% | +24.5% | -17.8% | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | +51.3% | – | – |
| EPS | +51.5% | – | – |
| Share price | – | +203.4% (2y) | +535.7% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 79 | 84 |
| Borrowings | 0 | 0 |
| Cash & equivalents | 42 | 42 |
| Total assets | 80 | 88 |
| Fixed assets | 0 | 0 |
| Investments | 2 | 2 |
| Receivables | 3 | 2 |
| Inventory | 0 | 0 |
| Payables | 0 | 0 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 36 | -2 |
| Cash from investing | 6 | 2 |
| Cash from financing | 0 | 0 |
| Capex | 0 | 0 |
| Free cash flow | 36 | -2 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 6.6% | 5.1% |
| ROCE % | 8.9% | 6.7% |
| Debtor days | 376 | – |
| Inventory days | 0 | – |
| Payable days | 19 | – |
| Cash conversion cycle (days) | 357 | – |
| Working capital days | 10,732 | – |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| TRANSCHEM | ₹505 cr | 75.1x | 6.0x | 8.2% | 10.3% | – | – | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2001-09-10 | Dividend | NIL Dividend |
| 2000-10-30 | Dividend | NIL Dividend |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | TRANSCHEM |
| BSE code | 500422 |
| ISIN | INE019B01010 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.